Generate a tailored SOP for Dr. Carolyn Felix. Improve your application with a focused, well-structured draft.
Carolyn Felix, M.D. is a professor in the Department of Pediatrics at the University of Pennsylvania. Her research focuses on understanding the causes and consequences of MLL (KMT2A) translocations, which are significant in pediatric leukemia, including ultra-high-risk infant leukemia cases associated with chemotherapy. Dr. Felix has pioneered methodologies like panhandle PCR to detect and characterize translocations involving the MLL gene. Her work suggests that DNA damage from topoisomerase II (TOP2) poisons contributes to these translocations during prenatal exposure, leading to therapy-related leukemias in infants. She is dedicated to bridging basic science with clinical research, aiming to develop targeted treatments that reduce toxic side effects and improve outcomes for patients with MLL-rearranged leukemias. Her ongoing projects utilize zebrafish models to explore the origins of leukemia and investigate new therapeutic targets, showcasing her integrative approach that spans cellular biology, genetics, and clinical applications. Dr. Felix's insights into leukemia prevention and treatment highlight her commitment to transforming pediatric oncology practices.
Wharton Doctoral programs cover fields like Finance, Marketing, Management, and Operations, Information and Decisions.